Up 37% Since August, Is It Safe to Buy UnitedHealth Group Stock Again?

UnitedHealth reported Q3 revenue of $113.2 billion, up 12% year-over-year, while net margin narrowed to 2.1%; management raised full-year EPS guidance modestly to at least $14.90 (from $14.65). The stock has rallied ~37% since August after Berkshire Hathaway opened a position and its P/E moved from roughly 10 to 17, but rising costs, higher utilization, exits from some Medicare Advantage markets and an ongoing DOJ billing investigation leave material near-term uncertainty for earnings and valuation.

Analysis

Market structure: UnitedHealth's pullback from select Medicare Advantage markets benefits regional MA incumbents (Humana, Elevance) and PBMs that can pick up volume; hospitals/providers face near-term higher utilization/collections pressure. Exiting low-margin markets should mechanically lift consolidated margin by an estimated 100–200bps over 12–24 months if utilization normalizes, but cedes local pricing power to competitors, fragmenting market share regionally.

Risk assessment: The largest tail is regulatory/legal (DOJ) — a civil settlement or clawback >$5B would cut ~$3–5 of FY EPS and likely widen UNH credit spreads by 50–150bps; immediate shock risk (days) is high volatility, medium-term (1–3 quarters) earnings/guidance risk, long-term (12–24 months) depends on Optum’s ability to offset insurance headwinds. Hidden dependencies include Medicare Advantage coding risk and Optum’s outsourced services revenue concentration; catalysts are DOJ filings, Berkshire adjustments, and the next 60–90 day earnings/guidance cycle.

Trade implications: Tactical long exposure to UNH is reasonable given P/E ~17 versus historical 18–22 if hedged — consider 2–3% position with downside protection. Use options to compress tail risk: 6–9 month put spreads or collar structures; pair trades (long UNH vs short ELV/HUM) express conviction in UNH’s scale recovery over 3–12 months. Credit and equity vol will reprice on legal news — buy protection ahead of key catalysts.

Contrarian angles: The market may underweight Optum’s margin levers and overprice legal certainty; conversely Berkshire’s stake can be temporary and creates re-sell risk. Similar insurer probes have caused 6–18 month drawdowns followed by recovery if reserves are finite — trade sizing and explicit legal-trigger exits are therefore critical.

Key Decisions for Investors

• Establish a tactical 2% long position in UNH (ticker UNH) now; hedge with a 6–9 month put spread: buy 15% OTM put and sell 30% OTM put to cap cost. Target hold 3–12 months; add second tranche if UNH trades down 10% or P/E falls to ≤14.
• Implement a pair trade: long UNH (2% notional) vs short ELV (Elevance) (1.5% notional) to play relative execution; horizon 3–12 months. Close if UNH underperforms ELV by >15% or if UNH announces reserve >$3B for legal matters.
• If concerned about downside, buy a 6-month UNH 10–15% OTM put (outright) sized to cover 1–3% of portfolio loss risk; alternatively use a collar (sell 3-month 5% OTM calls) to finance protection. Exit protection if DOJ declines to file within 90 days or implied vol collapses >40%.
• Reduce 3–5% exposure to mid/small-cap managed-care names and redeploy into higher-quality PBM/health-services exposures (e.g., CVS) or cash until 1–2 quarterly earnings cycles clarify utilization trends; monitor DOJ filings and next two UNH earnings (next 60–90 days) as decision points.